{"result": {"id": "763d145e-a67c-470f-920f-296bd064619b", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>PEOPLE'S MEDICAL PUBLISHING HOUSE<|>ORGANIZATION<|>A publishing house based in Beijing that published a medical text in 2015\")\n##\n(\"entity\"<|>ZHANG B<|>PERSON<|>Co-author of a study on polypharmacy in elderly patients published in the Chinese Journal of Geriatrics\")\n##\n(\"entity\"<|>YAN X L<|>PERSON<|>Co-author of a study on polypharmacy in elderly patients published in the Chinese Journal of Geriatrics\")\n##\n(\"entity\"<|>WANG Q M<|>PERSON<|>Co-author of a study on polypharmacy in elderly patients published in the Chinese Journal of Geriatrics\")\n##\n(\"entity\"<|>KAKU K<|>PERSON<|>Author of a study on the efficacy of voglibose in type 2 diabetes published in Expert Opinion on Pharmacotherapy\")\n##\n(\"entity\"<|>BALFOUR J A<|>PERSON<|>Co-author of a study on acarbose and its therapeutic use in diabetes mellitus published in Drugs\")\n##\n(\"entity\"<|>MCTAVISH D<|>PERSON<|>Co-author of a study on acarbose and its therapeutic use in diabetes mellitus published in Drugs\")\n##\n(\"entity\"<|>AHR H J<|>PERSON<|>Co-author of a study on the pharmacokinetics of acarbose published in Arzneimittelforschung\")\n##\n(\"entity\"<|>BOBERG M<|>PERSON<|>Co-author of a study on the pharmacokinetics of acarbose published in Arzneimittelforschung\")\n##\n(\"entity\"<|>KRAUSE H P<|>PERSON<|>Co-author of a study on the pharmacokinetics of acarbose published in Arzneimittelforschung\")\n##\n(\"entity\"<|>MIURA T<|>PERSON<|>Co-author of a study on the impairment of absorption of digoxin by acarbose published in the Journal of Clinical Pharmacology\")\n##\n(\"entity\"<|>UENO K<|>PERSON<|>Co-author of a study on the impairment of absorption of digoxin by acarbose published in the Journal of Clinical Pharmacology\")\n##\n(\"entity\"<|>TANAKA K<|>PERSON<|>Co-author of a study on the impairment of absorption of digoxin by acarbose published in the Journal of Clinical Pharmacology\")\n##\n(\"entity\"<|>MORREALE A P<|>PERSON<|>Co-author of a study on the probable interaction of warfarin and acarbose published in the American Journal of Health-System Pharmacy\")\n##\n(\"entity\"<|>JANETZKY K<|>PERSON<|>Co-author of a study on the probable interaction of warfarin and acarbose published in the American Journal of Health-System Pharmacy\")\n##\n(\"entity\"<|>DASH R P<|>PERSON<|>Co-author of a study on the clinical drug-drug interaction potential of α-glucosidase inhibitors published in Xenobiotica\")\n##\n(\"entity\"<|>BABU R J<|>PERSON<|>Co-author of a study on the clinical drug-drug interaction potential of α-glucosidase inhibitors published in Xenobiotica\")\n##\n(\"entity\"<|>SRI NIVAS N R<|>PERSON<|>Co-author of a study on the clinical drug-drug interaction potential of α-glucosidase inhibitors published in Xenobiotica\")\n##\n(\"entity\"<|>SCHEEN A J<|>PERSON<|>Author of a study on Dipeptidylpeptidase-4 inhibitors and drug-drug interactions published in Clinical Pharmacokinetics\")\n##\n(\"entity\"<|>CHEN L M<|>PERSON<|>Author of a study comparing the pharmacokinetics and pharmacological activities of two peptidyl peptidase IV inhibitors published in the Chinese Journal of Diabetes Mellitus\")\n##\n(\"entity\"<|>GRAEFE-MODY U<|>PERSON<|>Co-author of a study on clinical aspects of drug interactions\")\n##\n(\"entity\"<|>RETLICH S<|>PERSON<|>Co-author of a study on clinical aspects of drug interactions\")\n##\n(\"entity\"<|>FRIEDRICH C<|>PERSON<|>Co-author of a study on clinical aspects of drug interactions\")\n##\n(\"relationship\"<|>ZHANG B<|>YAN X L<|>Co-authors of a study on polypharmacy in elderly patients<|>8\")\n##\n(\"relationship\"<|>ZHANG B<|>WANG Q M<|>Co-authors of a study on polypharmacy in elderly patients<|>8\")\n##\n(\"relationship\"<|>YAN X L<|>WANG Q M<|>Co-authors of a study on polypharmacy in elderly patients<|>8\")\n##\n(\"relationship\"<|>BALFOUR J A<|>MCTAVISH D<|>Co-authors of a study on acarbose and its therapeutic use in diabetes mellitus<|>8\")\n##\n(\"relationship\"<|>AHR H J<|>BOBERG M<|>Co-authors of a study on the pharmacokinetics of acarbose<|>8\")\n##\n(\"relationship\"<|>AHR H J<|>KRAUSE H P<|>Co-authors of a study on the pharmacokinetics of acarbose<|>8\")\n##\n(\"relationship\"<|>BOBERG M<|>KRAUSE H P<|>Co-authors of a study on the pharmacokinetics of acarbose<|>8\")\n##\n(\"relationship\"<|>MIURA T<|>UENO K<|>Co-authors of a study on the impairment of absorption of digoxin by acarbose<|>8\")\n##\n(\"relationship\"<|>MIURA T<|>TANAKA K<|>Co-authors of a study on the impairment of absorption of digoxin by acarbose<|>8\")\n##\n(\"relationship\"<|>UENO K<|>TANAKA K<|>Co-authors of a study on the impairment of absorption of digoxin by acarbose<|>8\")\n##\n(\"relationship\"<|>MORREALE A P<|>JANETZKY K<|>Co-authors of a study on the probable interaction of warfarin and acarbose<|>8\")\n##\n(\"relationship\"<|>DASH R P<|>BABU R J<|>Co-authors of a study on the clinical drug-drug interaction potential of α-glucosidase inhibitors<|>8\")\n##\n(\"relationship\"<|>DASH R P<|>SRI NIVAS N R<|>Co-authors of a study on the clinical drug-drug interaction potential of α-glucosidase inhibitors<|>8\")\n##\n(\"relationship\"<|>BABU R J<|>SRI NIVAS N R<|>Co-authors of a study on the clinical drug-drug interaction potential of α-glucosidase inhibitors<|>8\")\n##\n(\"relationship\"<|>GRAEFE-MODY U<|>RETLICH S<|>Co-authors of a study on clinical aspects of drug interactions<|>8\")\n##\n(\"relationship\"<|>GRAEFE-MODY U<|>FRIEDRICH C<|>Co-authors of a study on clinical aspects of drug interactions<|>8\")\n##\n(\"relationship\"<|>RETLICH S<|>FRIEDRICH C<|>Co-authors of a study on clinical aspects of drug interactions<|>8\")\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166569, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1700, "prompt_tokens": 2774, "total_tokens": 4474, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 982}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 作用基础与临床［J］.2 版 . 北京： 人民卫生出版社，2015.\n［ 10］张波， 闫雪莲，王秋梅，等 . 重视老年人多重用药问题［J］. 中华老年医学杂，2012，31（ 2 ）：171-174.DOI ：10.3760/cma. j.issn.0254-9026.2012.02.024.\n　ZHANG B ，YAN X L ，WANG Q M ，et al.Attaching great importance to polypharmacy in elderly patients［J］.Chinese Journal of Geriatrics ，2012 ，31（ 2 ）： 171-174.DOI： 10.3760/cma. j.issn.0254-9026.2012.02.024.\n［ 11 ］KAKU K.Efficacy of voglibose in type 2 diabetes ［J］ .Expert Opin P harmacother ，2014 ， 15（ 8 ）： 1 181-1 190 . DOI： 10.1517/14656566.2014.918956.\n［ 12］BALFOUR J A ，MCTAVI SH D .Acarbose.An update of its pharmacology and therapeutic use in diabetes mellitus［J］.Drugs， 1993，46（ 6 ）：1025-1054.\n［ 13］AHR H J ，BOBERG M ，KRAUSE H P ，et al.Pharmacokinetics of acarbose.Part      Ⅰ ：absorption ，concentration  in plasma， metabolism and excretion after single administration of ［ 14C ］ acarbose to rats ，dogs and man［J］ .Arzneimittelforschung， 1989 ，39（ 10 ）：1254-1260.\n［ 14］MIURA T，UENO K，TANAKA K，et al.Impairment of absorption of digoxin by acarbose［J］.J Clin Pharmacol ，1998 ，38（ 7 ）： 654-657.\n［ 15］MORREALE A P，JANETZKY K.Probable interaction of warfarin and acarbose［J］.Am J Health Syst Pharm ，1997 ，54（ 13 ）： 1551-1552.\n［ 16］DASH R P ，BABU R J ，SRI NIVAS N R.Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose ，voglibose and miglitol in the treatment of type 2 diabetes mellitus［J］.Xenobiotica ， 2018，48（ 1 ）：89-108.DOI ：10.1080/00498254.2016.1275063.\n［ 17］SCHEEN A J.Dipeptidylpeptidase-4 inhibitors （ gliptins）：focus on drug-drug interactions［J］.Clin Pharmacokinet，2010，49（ 9 ）： 573-588.DOI：10.2165/11532980-000000000-00000.\n［ 18］陈莉明 . 二肽基肽酶Ⅳ抑制剂类口服降糖药的药化性质和药理 活性综合比较分析［J］ . 中华糖尿病杂志，2016 ，8（ 8 ）： 508-510.DOI：10.3760/cma.j.issn.1674-5809.2016.08.014.\n　CHEN L M.Comparative of the pharmacokinetics and pharmacological activities of two peptidyl peptidase  Ⅳ inhibitors oral antidiabetic drugs［J］.Chinese Journal of Diabetes Mellitus，2016 ，8（ 8 ）： 508-510.DOI：10.3760/cma.j.issn.1674-5809.2016.08.014.\n［ 19］GRAEFE-MODY U ，RETLICH S ，FRIEDRICH C.Clinical\n\n\n　　　　　　　　　　　　　\n\n中英文全称、缩写及概念解释\n　　　· Ⅰ相药物代谢酶细胞色素 P450（CYP450）： 存在于多种组织和器官中，构成一个血红素硫醇盐蛋 白超家族，在肝脏中的含量最丰富，与肝脏疾病关系 密切。CYP450 是一个单氧化酶家族，对人类的 Ⅰ相 药物代谢具有重要意义，能催化大量内源性和外源性 复合物的代谢，包\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_8b9962c27a763f1ca955c0bdc8dd6f6259e8451e24066456e24d6c5fe4840ada_v2"}